The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review.
By itself, glucagon-like peptide-1(GLP-1) appears to be an excellent drug for appetite control and the treatment of obesity. Unfortunately, few enzymes, such as IV dipeptidyl peptidase and renal excretin, degrade and render GLP-1 inactive within minutes. A receptor agonist, exendin-4, with a longer biological half-life than GLP-1, has been tried. Subcutaneous injection of exendin-4 or continuous IV injection of GLP-1 warrants further research and investigation.
Frezza
Eldo E
EE
Division of General Surgery, Department of Surgery, Texas Tech University Health Sciences Center, MOP Building, Suite 380, 3502 9th Street, Lubbock, TX 79145, USA. eldo.frezza@ttuhsc.edu
Wachtel
Mitchell S
MS
Chiriva-Internati
Maurizio
M
D000818:Animals; D001066:Appetite / Q000502:physiology*; D015390:Gastric Bypass; D054439:Ghrelin; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D009765:Obesity / Q000503:physiopathology*; D018384:Oxidative Stress / Q000502:physiology*; D053772:Oxyntomodulin / Q000502:physiology; D036361:Peptide Hormones / Q000502:physiology; D019894:Peptide YY / Q000502:physiology
D054439:Ghrelin; D053772:Oxyntomodulin; D036361:Peptide Hormones; D019894:Peptide YY; D052216:Glucagon-Like Peptide 1